Key result
The weighted national seroprevalence of hepatitis E virus in the U.S. was 6.0% (95% CI 5.1%-6.9%), with older age remaining the only independent predictor of seropositivity.
Why the study?
What is the seroprevalence of hepatitis E virus (HEV) infection in the United States general population?
Cross-Sectional (n=8,814)
Yes
What is the seroprevalence of hepatitis E virus (HEV) infection in the United States general population?
The seroprevalence of HEV in the US is 6.0%, which is approximately one-third as high as previously reported estimates.
Indicates lower U.S. HEV seroprevalence than prior estimates; challenges historical data and leaves open updated risk assessments.
UNLABELLED: Analysis of the National Health and Nutrition Evaluation Survey (NHANES) 1988-1994 dataset found a relatively high seroprevalence (21%) of hepatitis E virus (HEV) infection in the U.S. general population. Using data obtained within the NHANES 2009-2010 survey, where a high performance assay for HEV was used, we estimated the weighted seroprevalence of HEV infection among U.S. individuals 6 years and older. We also evaluated factors associated with HEV seropositivity. A total of 8,814 individuals were included in the analysis. The median age of study participants was 37 years (interquartile range [IQR] 17-58 years), with 51.2% being female. The weighted national seroprevalence of HEV was 6% (95% confidence interval [CI] 5.1%-6.9%). About 0.5% of those with HEV had evidence of recent exposure (immunoglobulin M-positive). In the univariate analyses, factors associated with HEV seropositivity were increasing age (P-trend<0.001), birth outside of the U.S., Hispanic race, and "meat" consumption (>10 times/month). No significant association was observed with low socioeconomic status, water source, or level of education. In the multivariate analysis, only older age remained predictive of HEV seropositivity. CONCLUSION: The weighted national seroprevalence of HEV in the U.S. is much less than previously reported. Using data obtained with a high performance assay, the seroprevalence of HEV was estimated at 6.0% in the U.S. Based on these results, the seroprevalence of HEV is only one-third as high as previously reported.
No takes yet. Share an insight, caveat, or question.
Ditah et al. (2014) conducted a cross-sectional in Hepatitis E virus (HEV) infection (n=8,814). General US population was evaluated on HEV seroprevalence (95% CI 5.1-6.9). The weighted national seroprevalence of hepatitis E virus in the U.S. was 6.0% (95% CI 5.1%-6.9%), with older age remaining the only independent predictor of seropositivity.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: